172 related articles for article (PubMed ID: 7545163)
1. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia.
de Jong R; ten Hoeve J; Heisterkamp N; Groffen J
J Biol Chem; 1995 Sep; 270(37):21468-71. PubMed ID: 7545163
[TBL] [Abstract][Full Text] [Related]
2. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene.
Salgia R; Pisick E; Sattler M; Li JL; Uemura N; Wong WK; Burky SA; Hirai H; Chen LB; Griffin JD
J Biol Chem; 1996 Oct; 271(41):25198-203. PubMed ID: 8810278
[TBL] [Abstract][Full Text] [Related]
3. BCR/ABL-induced leukemogenesis causes phosphorylation of Hef1 and its association with Crkl.
de Jong R; van Wijk A; Haataja L; Heisterkamp N; Groffen J
J Biol Chem; 1997 Dec; 272(51):32649-55. PubMed ID: 9405482
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia.
ten Hoeve J; Arlinghaus RB; Guo JQ; Heisterkamp N; Groffen J
Blood; 1994 Sep; 84(6):1731-6. PubMed ID: 7521685
[TBL] [Abstract][Full Text] [Related]
5. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells.
Nichols GL; Raines MA; Vera JC; Lacomis L; Tempst P; Golde DW
Blood; 1994 Nov; 84(9):2912-8. PubMed ID: 7524758
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine phosphorylation of murine Crkl.
de Jong R; Haataja L; Voncken JW; Heisterkamp N; Groffen J
Oncogene; 1995 Oct; 11(8):1469-74. PubMed ID: 7478571
[TBL] [Abstract][Full Text] [Related]
7. Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells.
Bhat A; Kolibaba K; Oda T; Ohno-Jones S; Heaney C; Druker BJ
J Biol Chem; 1997 Jun; 272(26):16170-5. PubMed ID: 9195915
[TBL] [Abstract][Full Text] [Related]
8. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells.
Salgia R; Uemura N; Okuda K; Li JL; Pisick E; Sattler M; de Jong R; Druker B; Heisterkamp N; Chen LB
J Biol Chem; 1995 Dec; 270(49):29145-50. PubMed ID: 7493940
[TBL] [Abstract][Full Text] [Related]
9. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
Sattler M; Salgia R; Okuda K; Uemura N; Durstin MA; Pisick E; Xu G; Li JL; Prasad KV; Griffin JD
Oncogene; 1996 Feb; 12(4):839-46. PubMed ID: 8632906
[TBL] [Abstract][Full Text] [Related]
10. Cellular interactions of CRKL, and SH2-SH3 adaptor protein.
ten Hoeve J; Kaartinen V; Fioretos T; Haataja L; Voncken JW; Heisterkamp N; Groffen J
Cancer Res; 1994 May; 54(10):2563-7. PubMed ID: 8168080
[TBL] [Abstract][Full Text] [Related]
11. The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins.
Uemura N; Salgia R; Li JL; Pisick E; Sattler M; Griffin JD
Leukemia; 1997 Mar; 11(3):376-85. PubMed ID: 9067577
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.
Jain SK; Langdon WY; Varticovski L
Oncogene; 1997 May; 14(18):2217-28. PubMed ID: 9174058
[TBL] [Abstract][Full Text] [Related]
13. Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells.
Sattler M; Pride YB; Quinnan LR; Verma S; Malouf NA; Husson H; Salgia R; Lipkowitz S; Griffin JD
Oncogene; 2002 Feb; 21(9):1423-33. PubMed ID: 11857085
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site.
de Jong R; ten Hoeve J; Heisterkamp N; Groffen J
Oncogene; 1997 Feb; 14(5):507-13. PubMed ID: 9053848
[TBL] [Abstract][Full Text] [Related]
15. LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia.
Frietsch JJ; Kastner C; Grunewald TG; Schweigel H; Nollau P; Ziermann J; Clement JH; La Rosée P; Hochhaus A; Butt E
Oncotarget; 2014 Jul; 5(14):5257-71. PubMed ID: 24913448
[TBL] [Abstract][Full Text] [Related]
16. The two major sites of cbl tyrosine phosphorylation in abl-transformed cells select the crkL SH2 domain.
Andoniou CE; Thien CB; Langdon WY
Oncogene; 1996 May; 12(9):1981-9. PubMed ID: 8649859
[TBL] [Abstract][Full Text] [Related]
17. Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients.
Kardinal C; Konkol B; Schulz A; Posern G; Lin H; Adermann K; Eulitz M; Estrov Z; Talpaz M; Arlinghaus RB; Feller SM
FASEB J; 2000 Aug; 14(11):1529-38. PubMed ID: 10928987
[TBL] [Abstract][Full Text] [Related]
18. Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells.
Sattler M; Salgia R
Leukemia; 1998 May; 12(5):637-44. PubMed ID: 9593259
[TBL] [Abstract][Full Text] [Related]
19. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia.
Oda T; Heaney C; Hagopian JR; Okuda K; Griffin JD; Druker BJ
J Biol Chem; 1994 Sep; 269(37):22925-8. PubMed ID: 8083188
[TBL] [Abstract][Full Text] [Related]
20. Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells.
Grumbach IM; Mayer IA; Uddin S; Lekmine F; Majchrzak B; Yamauchi H; Fujita S; Druker B; Fish EN; Platanias LC
Br J Haematol; 2001 Feb; 112(2):327-36. PubMed ID: 11167825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
